Articles published in Journal of Stem Cell Research & Therapy have been cited by esteemed scholars and scientists all around the world. Journal of Stem Cell Research & Therapy has got h-index 26, which means every article in Journal of Stem Cell Research & Therapy has got 26 average citations.
Following are the list of articles that have cited the articles published in Journal of Stem Cell Research & Therapy.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Year wise published articles |
59 | 65 | 23 | 13 | 36 |
Year wise citations received |
351 | 405 | 380 | 349 | 319 |
Journal total citations count | 3118 |
Journal Impact Factor | 1.64 |
Journal 5 years Impact Factor | 1.70 |
Journal CiteScore | 11.56 |
Journal h-index | 26 |
Alcohol and Cancer Stem Cells
Alcohol and Cancer Stem Cells
In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods
Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article
The role of TRIM family proteins in the regulation of cancer stem cell self-renewal
The role of TRIM family proteins in the regulation of cancer stem cell self-renewal
Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein
Editing the sickle cell disease mutation in human hematopoietic stem cells: comparison of endonucleases and homologous donor templates
Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line
Increased Cellular Levels of MicroRNA-9 and MicroRNA-221 Correlate with Cancer Stemness and Predict Poor Outcome in Human Breast Cancer
Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I
Editing a ?-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
Lentiviral and genome-editing strategies for the treatment of ?-hemoglobinopathies
The delivery challenge: fulfilling the promise of therapeutic genome editing
Priming human repopulating hematopoietic stem and progenitor cells for Cas9/sgRNA gene targeting
Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
Correction to: Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing
Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with ?-thalassemia major
Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells
Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency